Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors

Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositi...

Full description

Saved in:
Bibliographic Details
Main Authors Risi Roberto M, Hansen Todd M, Curtin Michael, Mastracchio Anthony, Penning Thomas, Gong Jianchun, Song Xiaohong, Dabbeeru Madhu Babu, Goswami Rajeev, Iguturi Omprakash Reddy, Tong Yunsong, Zhu Guidong, Tao Zhi-fu, Michaelides Michael, Miyashiro Juliem, Clark Richard F, Lai Chunqiu, Bruncko Milan, Ji Zhiqin, Souers Andrew, Frey Robin R, Woods Keith W, Florjancic Alan S
Format Patent
LanguageEnglish
Published 24.10.2017
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).
Bibliography:Application Number: US201414780018